Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the setting of World Federation of Haemophilia humanitarian aid programme

Lambert, Catherine;Meité, N'Dogomo;Sanogo, Ibrahima;Lobet, Sébastien;Hermans, Cédric
(2021) Haemophilia (Print) — Vol. 27, n° 1, p. 33-40 (2021)

Files

2021_Lambert_Haemophilia.pdf
  • Restricted Access
  • Adobe PDF
  • 399.49 KB
Request a copy

Details

Authors
Abstract
(en) INTRODUCTION: In sub-Saharan Africa, access to clotting factor concentrates (CFCs) is often extremely limited and published data on people with haemophilia on prophylaxis are almost not existent. AIMS AND METHODS: To assess the feasibility, barriers and outcomes of a low-dose and low-frequency prophylaxis with extended half-life (EHL) recombinant Fc fusion FVIII and FIX in Ivorian children on a two-year period in the setting of the World Federation of Hemophilia's (WFH) humanitarian aid programme. RESULTS: Twenty-five boys with haemophilia were included. Mean (SD) age at inclusion was 5.6 (2.5) years. The median [range] follow-up duration was 17 [11-24] months. Regimen of prophylaxis was 20 IU kg-1 1×/week in haemophilia A and every 10 days in haemophilia B. We observed a maximal reduction by 87.6% of the annual spontaneous joint bleeding rate and a slight decrease in the total HJHS scores (p = .047). Adherence problems related to parents' low education level and shortage in CFCs were the main issues to carry out the programme. Inhibitors occurred in 12.5%. CONCLUSION: This study confirms the feasibility and efficacy of low-dose and low-frequency prophylaxis in young Ivorian children with haemophilia treated with EHL CFCs donated through the WFH humanitarian aid programme. This work also highlights the crucial role of adherence and the need for appropriate education to achieve prophylaxis. Finally, it reminds the paramount objective of achieving self-sufficient, sustainable and available haemophilia replacement therapy for all worldwide.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lambert, C., Meité, N., Sanogo, I., Lobet, S., & Hermans, C. (2021). Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the setting of World Federation of Haemophilia humanitarian aid programme. Haemophilia (Print), 27(1), 33-40. https://doi.org/10.1111/hae.14216 (Original work published 2021)